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A B S T R A C T
In order to assess the diagnostic value of procalcitonin, 158 patients with febrile neutropenia from
centres across Europe were studied. Patients with fever were diagnosed on the basis of either: (1)
clinical, radiological and microbiological criteria; or (2) the procalcitonin value. In the latter case,
concentrations of 0.5–1.0 ng ⁄mL were considered diagnostic of localised infection, concentrations of
1.0–5.0 ng ⁄mL of bacteraemia, and concentrations of > 5.0 ng ⁄mL of severe sepsis. Procalcitonin and
C-reactive protein were estimated daily in serum by immunochemiluminescence and nephelometry,
respectively. Overall, the sensitivity (specificity) of procalcitonin for bacteraemia was 44.2% (64.3%) at
concentrations of 1.0–5.0 ng ⁄mL, and 83.3% (100%) for severe sepsis at concentrations of > 5.0 ng ⁄mL. It
was concluded that procalcitonin is a marker strongly suggestive of severe sepsis at concentrations of
> 5.0 ng ⁄mL. Estimated concentrations of < 0.5 ng ⁄mL indicate that infection is unlikely, but it was
observed that bacteraemia associated with coagulase-negative staphylococci may fail to elevate serum
procalcitonin levels.
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I N T R O D U C T I O N
Febrile neutropenia is a common syndrome in
patients with haematological malignancies. Subtle
clinical findings and lack of microbiological con-
firmation are often associated with these patients.
Moreover, clinical criteria for diagnosis of the
systemic inflammatory response syndrome and
sepsis [1] are difficult to apply because of the
presence of neutropenia. Thus, there is a need for
an indicator to unmask the cause of fever.
Procalcitonin (PCT) has been proposed as such
an indicator of systemic infection, as its concen-
tration is elevated in septic patients, even in the
presence of immunosuppression [2–4]. In order to
elucidate the value of PCT in diagnosing febrile
neutropenia, the present study investigated 158
patients from centres across Europe. The aim of
the study was to clarify the sensitivity of PCT as a
diagnostic marker, and to identify how the cause
of fever in neutropenia would be considered if
measuring PCT was the only available diagnostic
approach. As a consequence, its diagnostic value
could be evaluated for cases when clinical indices
of infection were lacking.
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P A T I E N T S A N D M E T H O D S
Initially, 181 patients were enrolled in a multicentre prospect-
ive clinical trial between June 1999 and December 2001. The
participating centres were: Institut J. Bordet, Belgium; Athens
General Hospital G. Gennimatas, Evangelismos General Hos-
pital, Metaxa Anticancer Centre, and Sismanoglion General
Hospital, Greece; Hospitals of Bolzano and Cisanello-Pisa,
Italy; Bratislava General Hospital, Slovakia; and Hospital G.
Maranon, Madrid, Spain. Complete data were available for 158
of the 181 patients (Table 1). All suffered from haematological
malignancies and presented with neutropenia (polymorphs
< 500 ⁄ lL) after anti-neoplastic chemotherapy, followed by the
development of fever. Following diagnosis of neutropenia,
blood was collected from one forearm vein; subsequent
samples were taken on a daily basis following onset of fever
until its resolution. Fever was considered as any single spike of
body temperature of > 38.5 C, or as any two or more spikes of
> 38 C within 12 h. Fever resolution was considered to have
occurred whenever body temperature decreased to £ 37.6 C
[5].
Blood was collected into pyrogen-free tubes and centri-
fuged briefly to separate the serum, which was then stored at
) 70 C until processed. Serum PCT was estimated with an
assay based on immunochemiluminescence (BRAHMS Diag-
nostica, Berlin, Germany; lower detection limit of 0.08 ng ⁄mL),
and C-reactive protein (CRP) was measured by nephelometry
(Boehring, Mannhein, Germany; lower detection limit of
3.2 mg ⁄L).
In order to facilitate statistical analysis, diagnosis in any
patient was based on either: (1) clinical observations combined
with radiological and microbiological findings; or (2) single
estimations of PCT levels following advent of fever.
For (1), patients were divided into six main categories
comparable to those used in previous studies [2]: i.e.,
patients with bacteraemia without severe sepsis; patients
with a microbiologically documented localised bacterial
infection; patients with severe sepsis; patients with a clinic-
ally documented localised infection; patients with systemic
mycosis; and patients with fever of unknown origin (FUO).
In order to establish the diagnosis, a complete examination of
the patient was performed following advent of fever. This
comprised cultures of blood, urine and sputum, blood gas
analysis, lung X-rays, and computed tomography of lungs
and upper or lower abdomen, whenever considered neces-
sary. Diagnosis of bacteraemia associated with coagulase-
negative staphylococci (CNS) was based on the isolation of
strains with identical antibiograms from at least two separate
blood cultures taken at different times. Severe sepsis was
recorded whenever fever was accompanied by signs of tissue
hypoperfusion, such as decreased urine output, metabolic
acidosis or deterioration of mental status [1]. FUO was
recorded when no cause of fever could be established after
three febrile days [5].
For (2), patients were divided into four main diagnostic
categories by a single measurement of the PCT level on
presentation according to the diagnostic cut-offs proposed
previously [6], namely:
• Bacteraemia: PCT level of 1.0–5.0 ng ⁄mL
• Severe sepsis: PCT level of > 5.0 ng ⁄mL
• Localised infection: PCT level of 0.5–1.0 ng ⁄mL
• FUO: PCT level of < 0.5 ng ⁄mL
For all patients categorised by criterion (1), PCT and CRP
levels on sequential days were expressed by their mean (± SE).
Statistical comparisons between groups of patients on the same
day of sampling were performed by Tukey’s test. PCT levels
on the day of presentation of fever were expressed by their
mean (± SE), separately for patients who eventually died and
for those who were resuscitated. The same analysis was
performed for patients with CNS bacteraemia, for bacteraemia
caused by other Gram-positive cocci, and for bacteraemia
caused by Gram-negative bacteria. Comparisons were per-
formed by ANOVA. Any p value £ 0.05 was considered to be
significant.
Table 1. Demographic data for
patients enrolled in the study
Category of infection
Bacteraemia
Localised
bacterial
infection
Severe
sepsis
Clinically
localised
infection
Systemic
mycosis
Fever of
unknown
origin
Number of patients 52 (32.1%) 14 (8.8%) 12(7.6%) 20 (12.7%) 5 (3.1%) 55 (34.0%)
Age in years (mean ± SD) 50.4 ± 18.2 53.3 ± 20.5 53.6 ± 15.0 52.3 ± 19.6 50.0 ± 20.9 49.1 ± 19.3
Male:female ratio 22:30 8:6 8:4 9:11 4:1 39:16
Underlying malignancy
(number of patients)
AML 32 5 7 11 2 30
NHL 7 4 2 2 – 11
ALL 11 3 1 4 2 11
Other 2 2 2 3 1 3
Underlying infection
Primary bacteraemia 31 – – – 1
UTI 1 7 3 – –
LRTI 3 3 5 9 3
Central venous catheter 17 1 1 1 –
Other – 3 3 10 1
Isolated pathogen
CNS 26 1
Streptococcus spp. 5 1
Escherichia coli 6 7
Pseudomonas aeruginosa 3 –
Klebsiella pneumoniae 2 2
Aspergillus spp. – – 4
Other 10 1 3 1
AML, acute myelogenous leukaemia; NHL, non-Hodgkin’s lymphoma; ALL, acute lymphoblastic leukaemia; LRTI,
lower respiratory tract infection; UTI, urinary tract infection; CNS, coagulase-negative staphylococci.
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Recipient operating characteristic (ROC) curves of the
sensitivity and specificity of PCT and CRP levels for the
diagnosis of bacteraemia and severe sepsis were constructed
according to (1). Patients with localised bacterial infections
were used as controls when designing the ROC curve for
bacteraemia, while patients with a localised clinical infection
were used as controls when designing the ROC curve for
severe sepsis.
R E S U L T S
For patients diagnosed by (1), the mean (± SE)
concentrations of PCT on advent of fever were
2.98 ± 1.03 ng ⁄mL in patients with bacteraemia,
0.98 ± 0.24 ng ⁄mL in patients with microbiologi-
cally documented localised infection, 14.54 ±
5.05 ng ⁄mL in patients with severe sepsis,
0.87 ± 0.23 ng ⁄mL in patients with clinically docu-
mented localised infection, and 1.11 ± 0.27 ng ⁄mL
in patients with FUO. Follow-up of these patients is
shown in Table 2. The mean PCT levels (ng ⁄mL)
of five patients with systemic mycosis were
1.17 ± 0.44, 0.42 ± 0.19, 0.86 ± 0.36 and 0.39 ±
0.18 on the first, second, third and fourth days of
fever, respectively. Follow-up of CRP levels is
shown in Table 3.
Twelve (7.6%) patients died while febrile.
Their mean PCT level on the first day of fever
was 20.45 ± 4.48 ng ⁄mL, compared to 9.79 ±
1.29 ng ⁄mL for patients surviving after the febrile
episode (p < 0.0001). Among patients with bac-
teraemia caused by CNS, other Gram-positive
cocci and Gram-negative bacteria, the mean
PCT levels (ng ⁄mL) on advent of fever were
0.83 ± 0.21, 3.22 ± 1.62 and 6.22 ± 2.49, respect-
ively. The distribution of PCT levels for these
patients, and their statistical comparisons, are
shown in Fig. 1.
Among 52 patients with bacteraemia diagnosed
by (1), 23 had PCT levels of 1.0–5.0 ng ⁄mL. At
that cut-off level, the sensitivity, specificity, pos-
itive and negative predictive values of PCT for
bacteraemia were 44.2%, 64.3%, 82.1% and
18.8%, respectively. The corresponding CRP val-
ues at a cut-off of ‡ 3.2 mg ⁄L were 34.6%, 21.4%,
62.1%, and 8.3%, respectively. Among 12 patients
with severe sepsis diagnosed by (1), ten had PCT
levels of > 5.0 ng ⁄mL. At that cut-off level, the
sensitivity, specificity, positive and negative pre-
dictive values of PCT for severe sepsis were
83.3%, 100%, 100%, and 90.9%, respectively. The
corresponding CRP values at a cut-off of
‡ 3.2 mg ⁄L were 100%, 5.0%, 38.7% and 100%,
respectively. Comparative ROC curves for the
diagnostic accuracy of PCT and CRP levels for the
diagnosis of bacteraemia and severe sepsis are
shown in Fig. 2.
If diagnosis was based on (2), 45 patients would
have been diagnosed with bacteraemia, 25 with a
localised infection, 17 with severe sepsis, and
71 with FUO. Mean PCT levels (ng ⁄mL) for these
patients were 2.32 ± 0.14, 0.71 ± 0.07, 17.53 ± 3.99,
and 0.23 ± 0.02, respectively. The correlation
between diagnosis by (1) and (2) is shown in
Table 4.
D I S C U S S I O N
Febrile neutropenia is a medical emergency
requiring prompt diagnosis of any underlying
Table 2. Daily follow-up of procalc-
itonin (PCT) levels of patients en-
rolled in the study, correlated with
the category of infection
Mean (± SE) PCT level (ng ⁄mL)
Bacteraemia
Localised
bacterial
infection
Severe
sepsis
Clinically
localised
infection
Fever of
unknown
origin
Afebrile neutropenia 0.85 ± 0.37 0.36 ± 0.10 0.47 ± 0.12 0.24 ± 0.02 0.59 ± 0.17
Advent of fever
1st day 2.98 ± 1.03a,b 0.98 ± 0.24c 14.54 ± 5.05d,e 0.87 ± 0.23g 1.11 ± 0.27
2nd day 2.33 ± 0.54a,b 0.74 ± 0.17c 14.48 ± 6.08d,f 1.99 ± 1.59g 0.91 ± 0.32
3rd day 1.57 ± 0.37a,b 0.81 ± 0.34c 12.76 ± 6.15d,f 1.02 ± 0.31g 1.14 ± 0.49
4th day 1.04 ± 0.26a,b 0.53 ± 0.17c 8.91 ± 2.31d,f 0.47 ± 0.15g 1.17 ± 0.52
Afebrile 1.30 ± 0.37 0.39 ± 0.20 8.67 ± 5.65 0.53 ± 0.15 0.72 ± 0.16
ap NS (non-significant) when comparing the PCT levels of patients with bacteraemia to those of patients with fever
of unknown origin (FUO).
bp NS when comparing the PCT levels of patients with bacteraemia to those of patients with localised bacterial
infections.
cp NS when comparing the PCT levels of patients with localised bacterial infections to those of patients with FUO.
dp < 0.0001 when comparing the PCT levels of patients with severe sepsis to those of patients with localised
infection.
ep 0.001 or fp < 0.0001 when comparing the PCT levels of patients with severe sepsis to those of patients with FUO.
gp NS when comparing the PCT levels of patients with clinically localised infections to those of patients with FUO.
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infection and early administration of antimicro-
bial agents. Clinical, microbiological and radiolo-
gical assessment of the patient often fails to reveal
the cause of fever. There has been much debate as
to whether PCT levels (elevated in systemic
infections) might be used to assess the febrile
neutropenic host [2–4]. The present multicentre
study investigated 158 patients with febrile neu-
tropenia, and clearly showed that PCT levels were
elevated significantly in patients with severe
sepsis compared to other patients (Table 2). In
contrast, although mean PCT levels on the first
day of fever were higher in patients with bacter-
aemia than in those with localised infections, this
difference was not statistically significant. This
lack of statistical significance can probably be
attributed to the fact that patients with bacterae-
mia caused by CNS and other isolates were
grouped together for analysis; the increase in
PCT levels was significantly higher in bacterae-
mia caused by Gram-negative bacteria than in
that caused by CNS (Fig. 1). Unlike that of PCT,
the CRP level was elevated in all febrile neutrop-
enic patients; however, the increase for severe
sepsis was remarkably higher than for the other
diagnostic categories (Table 3).
Conflicting results have been reported regard-
ing the diagnostic significance of PCT for sys-
temic mycosis, but only for a limited number of
patients [7]. The results in the present study
indicated that PCT levels in systemic mycosis
were comparable to or even lower than those of
patients with localised infections. Four of the
five cases of mycosis in the present study were
caused by Aspergillus spp.
The above results were in general agreement
with previous studies describing higher PCT levels
in patients with febrile neutropenia and bactaere-
mia or severe sepsis than in patients with localised
infections [2–4]. However, a major discrepancy
with these studies concerns the diagnostic signifi-
cance of PCT. Contrary to previous studies with
immunocompetent hosts [8], in which low PCT
levels excluded the presence of bacteraemia, the
present study indicated that low or normal PCT
levels did not exclude bacteraemia associated with
CNS. Elevated PCT levels were associated mostly
with bacteraemia caused by other species of Gram-
positive cocci or Gram-negative bacteria. This is
Table 3. Daily follow-up of C-react-
ive protein (CRP) levels of patients
enrolled in the study, correlated
with the category of infection
Mean (± SE) CRP level (mg ⁄L)
Bacteraemia
Localised
bacterial
infection
Severe
sepsis
Clinically
localised
infection
Fever of
unknown
origin
Afebrile neutropenia 54.8 ± 20.9 50.6 ± 39.9 96.3 ± 26.9 24.0 ± 23.2 29.6 ± 8.2
Advent of fever
1st day 89.7 ± 19.2a,b 94.9 ± 52.0c 228.6 ± 28.5d,f 51.1 ± 21.4I 82.5 ± 17.9
2nd day 123.9 ± 12.4a,b 90.6 ± 35.2c 214.2 ± 28.0e,g 129.0 ± 7.0I 76.1 ± 15.6
3rd day 123.8 ± 13.1a,b 90.1 ± 34.5c 205.0 ± 51.6e,h 102.0 ± 9.3I 87.3 ± 16.9
4th day 118.5 ± 26.5a,b 166.3 ± 69.9c 74.0 ± 4.0e,h 98.0 ± 15.0I 82.5 ± 20.0
Afebrile 77.7 ± 16.9 122.6 ± 33.9 86.7 ± 50.6 146.8 ± 53.2 53.2 ± 11.6
ap NS (non-significant) when comparing the CRP levels of patients with bacteraemia to those of patients with fever
of unknown origin (FUO).
bp NS when comparing the CRP levels of patients with bacteraemia to those of patients with localised bacterial
infections.
cp NS when comparing the CRP levels of patients with localised bacterial infections to those of patients with FUO.
dp 0.005 or eNS when comparing the CRP levels of patients with severe sepsis to those of patients with localised
infection.
fp 0.039, g0.001 or hNS when comparing the CRP levels of patients with severe sepsis to those of patients with FUO.
ip NS when comparing the CRP levels of patients with clinically localised bacterial to those of patients with FUO.
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Fig. 1. Distribution of concentrations of procalcitonin at
the time of fever manifestation among patients with
bacteraemia caused by coagulase-negative staphylococci,
other Gram-positive cocci and Gram-negative bacteria.
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also the main reason for the limited sensitivity of a
PCT cut-off value of 1.0 ng ⁄mL in diagnosing
bacteraemia with safety (Fig. 2). However, PCT
was found to indicate cases of severe sepsis reliably
whenever its level was > 5.0 ng ⁄mL.
The present study was the first to attempt to
diagnose clinical syndromes in the context of
febrile neutropenia on the sole basis of PCT levels.
The correlation between diagnosis on the basis of
clinical criteria or PCT levels revealed that PCT
could predict cases of FUO and cases of localised
infections safely (Table 4). The results also indi-
cated that PCT levels could detect patients with
severe sepsis accurately, with a high sensitivity
and positive predictive value. Although the sen-
sitivity of CRP for diagnosing severe sepsis was
also high, its specificity and positive predictive
value were very low. The strong diagnostic
association between PCT levels and severe sepsis
has already been shown elsewhere [9]. Although
the diagnostic accuracy of PCT for bacteraemia
was lower than for severe sepsis, PCT could
discriminate between systemic and localised bac-
terial infections, a result confirming those of other
studies [10,11]. CRP levels could not distinguish
between these conditions, irrespective of the
possible effect of the underlying malignancy on
its production [12].
Finally, it should be emphasised that PCT also
had a considerable prognostic value, since the
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Fig. 2. Comparative ROC curves (a) of procalcitonin and (b) of C-reactive protein for the diagnosis of bacteraemia and
severe sepsis. Diagnosis of bacteraemia and severe sepsis was based on clinical, radiological and microbiological criteria
(see Methods).
Table 4. Correlation between diag-
nosis of the cause of febrile neu-
tropenia by either (1) clinical criteria
plus radiological and microbiologi-
cal findings, or (2) procalcitonin
levels
Diagnosis by (1)b
Diagnosis by (2)a
Bacteraemia
Localised
infection
Severe
sepsis
Fever of
unknown origin Total
Bacteraemia 19 7 6 20 52
Localised bacterial infection 4 4 6 14
Severe sepsis 3 8 1 12
Localised clinical infection 5 6 9 20
Fever of unknown origin 10 8 3 34 55
Systemic fungosis 4 1 5
Total 45 25 17 71 158
aClinical critieria plus radiological and microbiological findings.
bProcalcitonin levels.
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final patient outcome correlated with the PCT
level on the first day of fever. The prognostic
significance of PCT has been shown already for
immunocompetent hosts [13] and children with
febrile neutropenia [14]. There is no doubt that
evaluation of a patient should rely always on
clinical findings. However, febrile neutropenia is
unique in that the clinical picture is often mis-
leading. The findings in the present study
revealed that PCT is a marker that might help
the clinician: i.e., concentrations of > 5.0 ng ⁄mL
are strongly suggestive of severe sepsis, levels of
1.0–5.0 ng ⁄mL of bacteremia, and levels of
0.5–1.0 ng ⁄mL of localised infection. Although
estimated concentrations of < 0.5 ng ⁄mL may
indicate that an infection is unlikely, it should
always be considered that bacteraemia caused by
CNS may fail to elevate serum PCT levels.
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